The Effects of Acylation Stimulating Protein Supplementation VS Antibody Neutralization on Energy Expenditure in Wildtype Mice
Overview
Authors
Affiliations
Background: Acylation stimulating protein (ASP) is an adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes. Previous studies have shown that ASP-deficient C3 knockout mice are hyperphagic yet lean, as they display increased oxygen consumption and fatty acid oxidation compared to wildtype mice. In the present study, antibodies against ASP (Anti-ASP) and human recombinant ASP (rASP) were tested in vitro and in vivo. Continuous administration for 4 weeks via osmotic mini-pump of Anti-ASP or rASP was evaluated in wildtype mice on a high-fat diet (HFD) to examine their effects on body weight, food intake and energy expenditure.
Results: In mature murine adipocytes, rASP significantly stimulated fatty acid uptake (+243% vs PBS, P < 0.05) while Anti-ASP neutralized the rASP response. Mice treated with Anti-ASP showed elevated energy expenditure (P < 0.0001), increased skeletal muscle glucose oxidation (+141%, P < 0.001), reduced liver glycogen (-34%, P < 0.05) and glucose-6-phosphate content (-64%, P = 0.08) compared to control mice. There was no change in body weight, food intake, fasting insulin, adiponectin, CRP or TG levels compared to controls. Interestingly, HFD mice treated with rASP showed the opposite phenotype with reduced energy expenditure (P < 0.0001) and increased body weight (P < 0.05), cumulative food intake (P < 0.0001) and liver glycogen content (+59%, P < 0.05). Again, there was no change in circulating insulin, adiponectin, CRP or TG levels, however, plasma free fatty acids were reduced (-48%, P < 0.05).
Conclusion: In vitro, Anti-ASP effectively neutralized ASP stimulated fatty acid uptake. In vivo, Anti-ASP treatment increased whole body energy utilization while rASP increased energy storage. Therefore, ASP is a potent anabolic hormone that may also be a mediator of energy expenditure.
Tumor Suppressor Par-4 Regulates Complement Factor C3 and Obesity.
Araujo N, Sledziona J, Noothi S, Burikhanov R, Hebbar N, Ganguly S Front Oncol. 2022; 12:860446.
PMID: 35425699 PMC: 9004617. DOI: 10.3389/fonc.2022.860446.
Association of serum complement C3 with metabolic syndrome components in normal weight obese women.
Karkhaneh M, Qorbani M, Mohajeri-Tehrani M, Hoseini S J Diabetes Metab Disord. 2018; 16:49.
PMID: 29299442 PMC: 5745599. DOI: 10.1186/s40200-017-0330-6.
The Controversial C5a Receptor C5aR2: Its Role in Health and Disease.
Zhang T, Garstka M, Li K J Immunol Res. 2017; 2017:8193932.
PMID: 28706957 PMC: 5494583. DOI: 10.1155/2017/8193932.
C3 Polymorphism Influences Circulating Levels of C3, ASP and Lipids in Schizophrenic Patients.
Nsaiba M, Lapointe M, Mabrouk H, Douki W, Gaha L, Perusse L Neurochem Res. 2015; 40(5):906-14.
PMID: 25720829 DOI: 10.1007/s11064-015-1543-z.
Al Riyami B, El-Tahir M, Al Maskari S, Johnson E, Saleh J J Nutr Metab. 2014; 2014:510916.
PMID: 25525514 PMC: 4267214. DOI: 10.1155/2014/510916.